Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

This study looks at switching newly diagnosed multiple myeloma patients from bortezomib (a standard drug) to carfilzomib (a similar but different drug in the same class) when side effects from bortezomib become too difficult to tolerate. **You may be eligible if...** - You are 18 or older and have been diagnosed with multiple myeloma - You are currently on your first round of bortezomib-based treatment (e.g., VRD, VTD, VCD, or PAD) - You have developed significant side effects from bortezomib, such as nerve pain (peripheral neuropathy), liver problems, or severe diarrhea — leading to a dose reduction or stopping bortezomib **You may NOT be eligible if...** - You have received more than one round of treatment for myeloma - You have severe heart problems (e.g., recent heart attack or poorly controlled heart failure) - You have active infections or other uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.